Search

Your search keyword '"Shannon, Kerwin"' showing total 606 results

Search Constraints

Start Over You searched for: Author "Shannon, Kerwin" Remove constraint Author: "Shannon, Kerwin"
606 results on '"Shannon, Kerwin"'

Search Results

1. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

3. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

4. Women and Members of Socially Diverse Groups in a Sport Management Program: Key Lessons from Creating and Leading a Student-Led Equity, Diversity, and Inclusion Club

5. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

7. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort

8. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

9. Uncovering the complex relationship between balding, testosterone and skin cancers in men

10. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach

11. Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy

13. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

17. A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).

18. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

19. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

20. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

21. Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting

23. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

24. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

28. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

32. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

33. Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma

34. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

36. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

37. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

39. ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma

40. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

41. Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy

42. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma

43. Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images

44. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers

45. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

46. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas

47. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

48. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

49. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

50. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

Catalog

Books, media, physical & digital resources